Company Overview
XERIS BIOPHARMA HOLDINGS, INC.
XERSRevenue vs. Cost of Revenue
Revenue
Cost of Revenue
Total Operating Expenses vs. Operating Income
Total Operating Expenses
Operating Income
Net Income
Net Income
Revenue
292M
2025 FY
Net Income
1M
2025 FY
Shares Outstanding
160M
2025 FY
EPS
0USD
2025 FY
Company Information
SIC Code
2834
CIK Code
1867096
Exchange
Nasdaq
Location
US